在过去的半个世纪，化疗、放疗、骨髓造血干细胞移植等综合性传统治疗已经挽救了无数淋巴细胞恶性肿瘤患儿的生命，但复发/难治性病例的预后不容乐观，因此急需新的治疗方案提高临床疗效。经过数十年的发展，免疫治疗在儿童淋巴细胞恶性肿瘤中已经取得显著成效，尤其是嵌合抗原受体T(chimeric antigen receptor T，CAR-T)、双特异性T细胞衔接抗体(bi-specific T cell engager，BiTE)和免疫检查点抑制剂(immune checkpoint blockader，ICB)，然而仍有部分患儿对免疫治疗抵抗。该文将围绕免疫治疗中研究较集中的CAR-T、BiTE、ICB三种方案，综述其在儿童白血病和淋巴瘤中的临床前和临床研究的进展，概述治疗局限性和可能提高疗效的优化方案。“,”In the last half-century, the multi-cooperation of conventional therapies including chemotherapy, radiotherapy and bone marrow hematopoietic stem cell transplantation has saved a lot of children with lymphocyte malignancies, but the outcomes of relapsed and/or refractory diseases remain dismal.Thus, it is in urgent need of novel approaches to improve clinical efficiency.After decades of rapid development, immunotherapy has achieved remarkable results from the treatment of pediatric lymphocyte malignancies, especially chimeric antigen receptors T(CAR-T), bi-specific T cell engager(BiTE), and immune checkpoint blockader(ICB). However, a part of patients is still resistant to immunotherapy.The review will focus on CAR-T, BiTE and ICB to elucidate the pre-clinical studies and clinical trials that have been intensively conducted in pediatric leukemia and lymphoma, as well as the brief introduction of their limitations and probably optimal strategies.